Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정일엽 | - |
dc.date.accessioned | 2018-03-20T02:33:00Z | - |
dc.date.available | 2018-03-20T02:33:00Z | - |
dc.date.issued | 2013-03 | - |
dc.identifier.citation | Hanyang medical reviews, 2013, 33(1), pp.65-74 | en_US |
dc.identifier.issn | 1738-429X | - |
dc.identifier.issn | 2234-4446 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.7599/hmr.2013.33.1.65 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/49377 | - |
dc.description.abstract | Eosinophil is one of the most enigmatic leukocytes that plays pleiotropic roles in initiation and propagation of inflammatory conditions, modulation of innate and adaptive immune responses, homeostasis, and remodeling and repair of diverse tissues in health and disease. Eosinophils arise from CD34+ hematopoietic cells in the bone marrow under the influence of transcription factors (C/EBPα and GATA-1) and hematopoietic cytokines (IL-5, IL-3, and GM-CSF). The unusually high numbers of eosinophils in blood and/or tissues, so-called hypereosinophilia, are often critically involved in pathophysiology of a wide variety of inflammatory diseases in many organs, including many allergic diseases (asthma, rhinitis, conjunctivitis, atopic dermatitis), gastrointestinal diseases (eosinophilic eosophagitis, ulcerative colitis, Crohn's disease, Duchenne's muscular dystrophy, idiopathic myositis), cancers (pancreas, bladder, liver, kidney, breast, melanoma, colon, glioblastoma, gastric, uterine, oral/nasal, lung), infectious diseases (helminth, bacteria, virus, fungi), transplantation rejection (lung, cardiac, corneal, skin, liver, and renal), reproduction, and autoimmune diseases. A dozen of therapeutic agents, notably including humanized anti-IL-5 monoclonal antibodies, that directly and indirectly target eosinophils have been developed and are studied extensively under clinical and preclinical trials. Some agents have been shown to have promising perspectives to hypereosinophilic diseases, especially against asthma exacerbations and hypereosinophilic syndromes. Further studies are required for discovery of the specific mechanisms of actions of the different eosinophil-targeted therapies, dosing strategies and treatment options with identification of biomarkers that can monitor and predict the responses. | en_US |
dc.description.sponsorship | 본 연구는 National Research Foundation (2011-0014580)에서 지원을 받아 수행하였다. 사진을 제공한 한양대학교 분자생명과학부 엄태기 학생과 편집을 도와준 강진현 박사, 그리고 호산구 분리를 위한 혈액을 공급한 순천향대학교 호흡기내과 김도진 교수에게 감사의표시를전한다 | en_US |
dc.language.iso | ko_KR | en_US |
dc.publisher | 한양대학교 | en_US |
dc.subject | Asthma | en_US |
dc.subject | Eosinophils | en_US |
dc.subject | Interleukin-5 | en_US |
dc.subject | Hypereosinophilic Syndrome | en_US |
dc.title | Hypereosinophilia-associated Diseases and the Therapeutic Agents in Development | en_US |
dc.type | Article | en_US |
dc.relation.volume | 33 | - |
dc.identifier.doi | 10.7599/hmr.2013.33.1.65 | - |
dc.relation.page | 65-74 | - |
dc.relation.journal | Hanyang Medical Reviews | - |
dc.contributor.googleauthor | 정일엽 | - |
dc.contributor.googleauthor | Chung, IlYup | - |
dc.relation.code | 2012247086 | - |
dc.sector.campus | S | - |
dc.sector.daehak | GRADUATE SCHOOL[S] | - |
dc.sector.department | DEPARTMENT OF BIONANOTECHNOLOGY | - |
dc.identifier.pid | iychu | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.